PostEra's machine learning technology is intended to accelerate the drug discovery process by designing novel molecular structures with optimised potency and drug-like properties. PostEra's approaches ...

SAN FRANCISCO, Dec. 7, 2020 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning solutions for preclinical drug discovery, today announced a strategic partnership with ...

Matthew Herper covers medical innovation — both its promise and its perils. SAN FRANCISCO — At the end of a roundtable lunch with a group of reporters, Pfizer CEO Albert Bourla became impassioned. He ...

PostEra, a biotechnology company specializing in machine learning solutions for preclinical drug discovery, has announced a strategic partnership with Pfizer Inc. (NYSE:PFE), to accelerate “small ...

Pfizer is strengthening its franchise in respiratory vaccines and treatments, Dr. Mikael Dolsten, the chief scientific officer, said on the Nov. 1 call. It’s racing against GSK and Moderna to be first ...

Vaccines to block COVID-19 that are in development by Moderna, Pfizer, AstraZeneca and others, and that are currently in Phase III clinical trials, may not do as well covering people of Black or Asian ...

View post: 60-year-old gym chain announces 23 location closures in shocking move View post: Are the Top 10% of American Consumers Really Driving 50% of Spending? Economists Debate. Are the Top 10% of ...

For drugmaker Pfizer, a fortune amassed in the COVID pandemic is now paving the path to pharma nirvana: a weight loss pill worth billions. The company has reaped nearly $100 billion from selling COVID ...